Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

BD Cheson, N Chua, J Mayer, G Dueck, M Trneny, K Bouabdallah, N Fowler, V Delwail, O Press, G Salles, JG Gribben, A Lennard, Elly Lugtenburg, G Fingerle-Rowson, F Mattiello, A Knapp, L H Sehn

Research output: Contribution to journalArticleAcademicpeer-review

65 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2259-+
JournalJournal of Clinical Oncology
Issue number22
Publication statusPublished - 2018

Cite this